ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells $169,621.00 in Stock

Posted by George Bondi on Aug 7th, 2026

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) EVP Mark Schneyer sold 5,849 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $29.00, for a total value of $169,621.00. Following the completion of the sale, the executive vice president directly owned 67,828 shares in the company, valued at approximately $1,967,012. This represents a 7.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock traded up $0.76 during trading on Friday, reaching $29.21. 1,782,652 shares of the company’s stock were exchanged, compared to its average volume of 1,684,264. ACADIA Pharmaceuticals Inc. has a 1-year low of $19.69 and a 1-year high of $29.48. The company has a market cap of $5.00 billion, a P/E ratio of 13.16, a PEG ratio of 19.47 and a beta of 0.81. The firm’s 50-day moving average price is $24.24 and its 200 day moving average price is $23.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.11. The business had revenue of $308.00 million for the quarter, compared to analyst estimates of $296.55 million. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.ACADIA Pharmaceuticals’s revenue was up 16.4% compared to the same quarter last year. During the same period last year, the firm posted $0.16 earnings per share. As a group, equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.4 EPS for the current year.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

Institutional Trading of ACADIA Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its stake in shares of ACADIA Pharmaceuticals by 74.4% in the 1st quarter. Royal Bank of Canada now owns 80,528 shares of the biopharmaceutical company’s stock valued at $1,338,000 after purchasing an additional 34,352 shares during the last quarter. AQR Capital Management LLC lifted its holdings in ACADIA Pharmaceuticals by 3.8% in the first quarter. AQR Capital Management LLC now owns 67,672 shares of the biopharmaceutical company’s stock valued at $1,124,000 after buying an additional 2,492 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in ACADIA Pharmaceuticals by 7.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,952 shares of the biopharmaceutical company’s stock valued at $1,498,000 after acquiring an additional 6,303 shares during the last quarter. Empowered Funds LLC bought a new stake in ACADIA Pharmaceuticals during the first quarter valued at $186,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in ACADIA Pharmaceuticals by 14.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 251,056 shares of the biopharmaceutical company’s stock worth $4,170,000 after acquiring an additional 31,931 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Bank of America restated a “buy” rating and issued a $14.50 price target on shares of ACADIA Pharmaceuticals in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $37.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Monday, June 29th. Citizens Jmp boosted their target price on shares of ACADIA Pharmaceuticals from $35.00 to $36.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Citigroup reiterated a “market outperform” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday. Finally, Canaccord Genuity Group boosted their target price on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.44.

Read Our Latest Report on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Profile

(Get Free Report)

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.